A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines
AbstractNanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity. The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL−1 and 2.4 mg mL−1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50% cell population at concentrations as low as 3 μg mL−1. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 2809 KB)
Share & Cite This Article
Alsuraifi, A.; Lin, P.K.T.; Curtis, A.; Lamprou, D.A.; Hoskins, C. A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines. Pharmaceuticals 2018, 11, 91.
Alsuraifi A, Lin PKT, Curtis A, Lamprou DA, Hoskins C. A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines. Pharmaceuticals. 2018; 11(4):91.Chicago/Turabian Style
Alsuraifi, Ali; Lin, Paul K.T.; Curtis, Anthony; Lamprou, Dimitrios A.; Hoskins, Clare. 2018. "A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines." Pharmaceuticals 11, no. 4: 91.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.